Meeting
2018 Genitourinary Cancers Symposium
Germline variant in SLCO2B1 and response to abiraterone acetate plus prednisone (AA) in men with metastatic castration-resistant prostate cancer (mCRPC).
Authors
Andrew W Hahn
University of Utah Hunstman Cancer Institute, Salt Lake City, UT
Andrew W Hahn , Darshan Patel , David Michael Gill , Camryn Froerer , Roberto Nussensveig , Austin Poole , Peter Hale , James M. Farnham , Benjamin Louis Maughan , Lisa A Cannon-Albright , Neeraj Agarwal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 311)
DOI
10.1200/JCO.2018.36.6_suppl.311
Abstract #
311
Poster Bd #
C2
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Germline variant alleles in rs12422149 of SLCO2B1 and response to abiraterone acetate (AA) in men with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Andrew W Hahn
Poster
2023 ASCO Annual Meeting
A prospective trial of apalutamide and abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.
First Author: Daniel J. George
Poster
2023 ASCO Annual Meeting
Phase 1/2a study of PRL-02, a long-acting intramuscular (IM) depot injection of abiraterone decanoate, in patients (pts) with advanced prostate cancer.
First Author: Neal D. Shore
Poster
2023 ASCO Genitourinary Cancers Symposium
Alliance A031902 (CASPAR): A randomized phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).
First Author: Arpit Rao